Plant Form Header
PlantForm, PharmaPraxis team up
for product development

PlantForm has signed a collaboration and license agreement with Brazil-based PharmaPraxis to develop, manufacture and commercialize biosimilar and/or biobetter versions of key biologic drugs, using PlantForm’s patented plant expression system.

The companies will initially develop biosimilar and/or biobetter versions of six leading monoclonal antibody products that have combined total annual global sales of $31.5 billion and are scheduled to lose patent protection within the next six years.

“PharmaPraxis is an important strategic partner for us,” said Dr. Don Stewart, PlantForm’s President and CEO. “We look forward to working together to bring highly valuable, lower-cost biopharmaceuticals to the Brazilian market and beyond.”

"Alternative routes of biopharmaceutical expression is a key element in PharmaPraxis' corporate strategy,” said PharmaPraxis CEO Eduardo Cruz. “We will bring valuable and less expensive biologic drugs to the Brazilian and Latin American markets."

PharmaPraxis is part of the Axis Biotec Brasil group of companies. Read the news release.
 

Minister’s visit spotlights Ontario innovation

Minister’s visit spotlights Ontario innovation

The Honourable Reza Moridi, Minister of Research and Innovation, met with PlantForm officials and toured the company’s research facility in Guelph April 3.

“As the new Minister of Research and Innovation, I have been touring the province, meeting with stakeholders and seeing the world-class innovation that takes place right here in Ontario,” said Minister Moridi (centre in photo above). “It’s exciting to see firsthand the research that is building the economy and creating the jobs of tomorrow.” See the news release and photos.


Board Chair contributes to international
pharma regs overview


Dr. Mark T. Goldberg, Chairman of PlantForm’s Board of Directors, has co-authored a chapter on Canadian pharmaceutical regulations in the recently published book: Nonclinical Safety Assessment: A Guide to International Pharmaceutical Regulations.
 


Join us online!
Get regular updates on our activities and industry news by following PlantForm on Twitter, LinkedIn and Facebook:

                          Facebook page - PlantForm

June 2013

OntarioInnovation profile

"The sky's the limit for this technology when it comes to biological-based drugs," says Dr. Chris Hall, PlantForm's Chief Scientific Officer, in a video produced by the Ontario Ministry of Research and Innovation.

The video also includes interviews with Dr. Don Stewart, President and CEO, and Dr. Steven Narod, Director of the Familial Breast Cancer Research Unit at Women’s College Research Institute in Toronto. Dr. Narod is a member of PlantForm’s Scientific Advisory Board.
Watch the video.

Worth 1,000 words

Check out our new infographic depicting the PlantForm manufacturing process.


Events
 
July 11
Dr. Don Stewart will present Looking beyond VCs: Alternative funding routes for early-stage life sciences companies, a webinar co-hosted by AppFolio SecureDocs. For more information, please email info@plantformcorp.com.
 

In the News 

PlantForm’s research greenhouse at the University of Guelph made for a stunning BioBusiness magazine cover shot. Read Pharming New Fields.


Management Team

Don Stewart, PhD
President & CEO

David Cayea, BA
Chief Operating Officer

Ron Hosking, CA
Chief Financial Officer

J. Christopher Hall, PhD
Chief Scientific Officer
PlantForm is a Canadian company focused on providing
low-cost therapeutic antibody drugs that fight cancer and other critical illnesses.

Our mailing address is:
1920 Yonge St, Suite 200
Toronto, Ontario
M4S 3E2  CANADA
For more information, contact:
Don Stewart
President & CEO
416-452-7242